You are here

New Drug Application Submitted to FDA for Single-Tablet HIV Regimen

Tenofovir-based treatment demonstrates high suppression rates

A new drug application (NDA) has been submitted to the FDA for an investigational, once-daily single tablet containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide (TAF) 10 mg (E/C/F/TAF) for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults.

According to the product’s developer (Gilead Sciences), the data submitted in the NDA support the use of the regimen in adult and adolescent treatment-naïve HIV-infected individuals, in virologically suppressed patients who switch regimens, and in those with renal impairment. If approved, E/C/F/TAF would be the first single-tablet regimen to contain TAF.

TAF is an investigational prodrug of tenofovir, the active agent in Viread (tenofovir disoproxil fumarate, Gilead Sciences). TAF is a more targeted form of tenofovir than that found in Viread, and it has demonstrated high antiviral efficacy at a dose that is 10 times lower, as well as improved renal and bone safety profiles.

The NDA for E/C/F/TAF was supported by 48-week data from two pivotal phase III studies in which the regimen met its primary objective of non-inferiority compared with Stribild (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg, Gilead Sciences) in treatment-naïve HIV patients. In these studies, E/C/F/TAF demonstrated improved renal and bone safety compared with Stribild.

The NDA was also supported by data from additional phase III studies that evaluated the TAF-based regimen in virologically suppressed HIV patients who switched to E/C/F/TAF and in patients with renal impairment.

Source: Gilead Sciences; November 6, 2014.

More Headlines

PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
National Statistics Report Factors In Race, Ethnicity for the First Time
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
California Woman Claimed Asbestos in Talc-Based Powder Caused Her Mesothelioma
Synergistic Effects Seen When Combined With Cisplatin in Mice
For Locally Advanced or Metastatic Triple-Negative Type Only